GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023
04 janv. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax
20 déc. 2022 09h00 HE
|
GeoVax, Inc.
First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) --...
GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors
07 déc. 2022 16h00 HE
|
GeoVax, Inc.
Dr. Morgan Brings Extensive COVID-19, Medical and Healthcare Management Expertise ATLANTA, GA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022
28 nov. 2022 10h15 HE
|
GeoVax, Inc.
Presentation to Focus on Progress of Pan-Coronavirus (Universal) Vaccines to Protect Against Evolving Variants ATLANTA, GA, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc....
GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update
09 nov. 2022 16h00 HE
|
GeoVax, Inc.
Phase 2 Clinical Trials Advance for COVID-19 and Immuno-Oncology Company Secures Rights to NIH-MVA for Protection Against Monkeypox and Smallpox ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) --...
GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
26 oct. 2022 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and...
GeoVax to Present at Vaccines Summit-2022
11 oct. 2022 09h00 HE
|
GeoVax, Inc.
Presentation to Focus on Development of Pan-Coronavirus (Universal) Vaccines to Protect Against Evolving Variants ATLANTA, GA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
GeoVax to Present at Upcoming Investor Conferences
06 oct. 2022 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 09h00 HE
|
GeoVax, Inc.
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine (GEO-CM04S1) and Phase 1/2 Clinical Trial for Advanced Head and Neck Cancer (Gedeptin®) ATLANTA, GA, Sept. 07, 2022 (GLOBE...
GeoVax Announces Addition to Its Board of Directors
01 sept. 2022 09h00 HE
|
GeoVax, Inc.
Nicole Lemerond, CFA, Brings Healthcare Finance Expertise to the GeoVax Board ATLANTA, GA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...